- Home
- Publications
- Publication Search
- Publication Details
Title
Neoadjuvant Therapy of Pancreatic Cancer: Definitions and Benefits
Authors
Keywords
-
Journal
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
Volume 18, Issue 8, Pages 1622
Publisher
MDPI AG
Online
2017-07-26
DOI
10.3390/ijms18081622
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 3rd St. Gallen EORTC Gastrointestinal Cancer Conference: Consensus recommendations on controversial issues in the primary treatment of pancreatic cancer
- (2017) Manfred P. Lutz et al. EUROPEAN JOURNAL OF CANCER
- Neoadjuvant Therapy Followed by Resection Versus Upfront Resection for Resectable Pancreatic Cancer: A Propensity Score Matched Analysis
- (2017) Ali A. Mokdad et al. JOURNAL OF CLINICAL ONCOLOGY
- Nutritional and Metabolic Derangements in Pancreatic Cancer and Pancreatic Resection
- (2017) Taylor Gilliland et al. Nutrients
- Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial.
- (2017) T. Conroy et al. JOURNAL OF CLINICAL ONCOLOGY
- Predictors and survival for pathologic tumor response grade in borderline resectable and locally advanced pancreatic cancer treated with induction chemotherapy and neoadjuvant stereotactic body radiotherapy
- (2016) Eric A. Mellon et al. ACTA ONCOLOGICA
- Neoadjuvant Therapy for Pancreatic Cancer
- (2016) Vivek Verma et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- CA19-9 decrease at 8 weeks as a predictor of overall survival in a randomized phase III trial (MPACT) of weeklynab-paclitaxel plus gemcitabine versus gemcitabine alone in patients with metastatic pancreatic cancer
- (2016) E. G. Chiorean et al. ANNALS OF ONCOLOGY
- Locally Advanced Pancreatic Cancer
- (2016) Thilo Hackert et al. ANNALS OF SURGERY
- Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma
- (2016) B. Ielpo et al. EJSO
- Implications of CA19-9 elevation for survival, staging, and treatment sequencing in intrahepatic cholangiocarcinoma: A national cohort analysis
- (2016) John R. Bergquist et al. JOURNAL OF SURGICAL ONCOLOGY
- FOLFIRINOX for locally advanced pancreatic cancer: a systematic review and patient-level meta-analysis
- (2016) Mustafa Suker et al. LANCET ONCOLOGY
- Perioperative chemotherapy is associated with a survival advantage in early stage adenocarcinoma of the pancreatic head
- (2016) Waseem Lutfi et al. SURGERY
- Preoperative radiochemotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer (PREOPANC trial): study protocol for a multicentre randomized controlled trial
- (2016) Eva Versteijne et al. Trials
- Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma – A population-based cohort study
- (2015) Knut J. Labori et al. ACTA ONCOLOGICA
- Treatment of 200 Locally Advanced (Stage III) Pancreatic Adenocarcinoma Patients With Irreversible Electroporation
- (2015) Robert C. G. Martin et al. ANNALS OF SURGERY
- Approach to Patients With Pancreatic Cancer Without Detectable Metastases
- (2015) Gregory M. Heestand et al. JOURNAL OF CLINICAL ONCOLOGY
- Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer
- (2015) Francesca Dimou et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Neoadjuvant Chemoradiotherapy and Surgery Versus Surgery Alone in Resectable Pancreatic Cancer: A Single-Center Prospective, Randomized, Controlled Trial Which Failed to Achieve Accrual Targets
- (2015) Riccardo Casadei et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Defining Borderline Resectable Pancreatic Cancer: Emerging Consensus for an Old Challenge
- (2015) Mokenge P. Malafa Journal of the National Comprehensive Cancer Network
- Extended Neoadjuvant Chemotherapy for Borderline Resectable Pancreatic Cancer Demonstrates Promising Postoperative Outcomes and Survival
- (2014) J. Bart Rose et al. ANNALS OF SURGICAL ONCOLOGY
- Serum CA 19-9 Response to Neoadjuvant Therapy is Associated with Outcome in Pancreatic Adenocarcinoma
- (2014) Brian A. Boone et al. ANNALS OF SURGICAL ONCOLOGY
- Sequential neoadjuvant chemoradiotherapy (CRT) followed by curative surgery vs. primary surgery alone for resectable, non-metastasized pancreatic adenocarcinoma: NEOPA- a randomized multicenter phase III study (NCT01900327, DRKS00003893, ISRCTN82191749)
- (2014) Michael Tachezy et al. BMC CANCER
- Systematic review of innovative ablative therapies for the treatment of locally advanced pancreatic cancer
- (2014) S. J. E. Rombouts et al. BRITISH JOURNAL OF SURGERY
- Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer
- (2014) Henriette Golcher et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Borderline resectable pancreatic cancer: A consensus statement by the International Study Group of Pancreatic Surgery (ISGPS)
- (2014) Maximilian Bockhorn et al. SURGERY
- Predictors for resectability and survival in locally advanced pancreatic cancer after gemcitabine-based neoadjuvant therapy
- (2014) Ying-Jui Chao et al. BMC Surgery
- A Single-Arm, Nonrandomized Phase II Trial of Neoadjuvant Gemcitabine and Oxaliplatin in Patients With Resectable Pancreas Adenocarcinoma
- (2013) Eileen M. OʼReilly et al. ANNALS OF SURGERY
- Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival
- (2013) Ching-Wei D. Tzeng et al. JOURNAL OF GASTROINTESTINAL SURGERY
- Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
- (2013) Daniel D. Von Hoff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Outcome after neoadjuvant chemoradiation and correlation with nutritional status in patients with locally advanced pancreatic cancer
- (2013) P. Naumann et al. STRAHLENTHERAPIE UND ONKOLOGIE
- Serum carbohydrate antigen 19-9 represents a marker of response to neoadjuvant therapy in patients with borderline resectable pancreatic cancer
- (2013) Ching-Wei D. Tzeng et al. HPB
- Computational Modeling of Pancreatic Cancer Reveals Kinetics of Metastasis Suggesting Optimum Treatment Strategies
- (2012) Hiroshi Haeno et al. CELL
- Pathological and clinical impact of neoadjuvant chemoradiotherapy using full-dose gemcitabine and concurrent radiation for resectable pancreatic cancer
- (2012) Masayuki Sho et al. Journal of Hepato-Biliary-Pancreatic Sciences
- Preoperative Chemoradiotherapy for Esophageal or Junctional Cancer
- (2012) P. van Hagen et al. NEW ENGLAND JOURNAL OF MEDICINE
- Prospective efficacy and safety study of neoadjuvant gemcitabine with capecitabine combination chemotherapy for borderline-resectable or unresectable locally advanced pancreatic adenocarcinoma
- (2012) Jae-Lyun Lee et al. SURGERY
- Arterial Resection During Pancreatectomy for Pancreatic Cancer
- (2011) Nathan Mollberg et al. ANNALS OF SURGERY
- Adjuvant gemcitabine versus NEOadjuvant gemcitabine/oxaliplatin plus adjuvant gemcitabine in resectable pancreatic cancer: a randomized multicenter phase III study (NEOPAC study)
- (2011) Stefan Heinrich et al. BMC CANCER
- Neoadjuvant GTX Chemotherapy and IMRT-based chemoradiation for borderline resectable pancreatic cancer
- (2011) Manish Patel et al. JOURNAL OF SURGICAL ONCOLOGY
- Using 18F-Fluorodeoxyglucose Positron Emission Tomography to Monitor Clinical Outcomes in Patients Treated With Neoadjuvant Chemo-Radiotherapy for Locally Advanced Pancreatic Cancer
- (2010) Minsig Choi et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
- (2010) Matthew H. G. Katz et al. ANNALS OF SURGICAL ONCOLOGY
- Preoperative/Neoadjuvant Therapy in Pancreatic Cancer: A Systematic Review and Meta-analysis of Response and Resection Percentages
- (2010) Sonja Gillen et al. PLOS MEDICINE
- Impact of Selection Bias on the Utilization of Adjuvant Therapy for Pancreas Adenocarcinoma
- (2009) Andrew J. Russ et al. ANNALS OF SURGICAL ONCOLOGY
- Pretreatment Assessment of Resectable and Borderline Resectable Pancreatic Cancer: Expert Consensus Statement
- (2009) Mark P. Callery et al. ANNALS OF SURGICAL ONCOLOGY
- Neoadjuvant Chemotherapy Generates a Significant Tumor Response in Resectable Pancreatic Cancer Without Increasing Morbidity
- (2008) Stefan Heinrich et al. ANNALS OF SURGERY
- Preoperative Gemcitabine and Cisplatin Followed by Gemcitabine-Based Chemoradiation for Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Gauri R. Varadhachary et al. JOURNAL OF CLINICAL ONCOLOGY
- Prospective Phase II Trial of Neoadjuvant Chemotherapy With Gemcitabine and Cisplatin for Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Stefan Heinrich et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Douglas B. Evans et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started